Search results for " Subcutaneous"

showing 10 items of 83 documents

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)

1990

• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms. ( Arch Intern Med. 1990;150:2401-2402)

Blood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousHypoglycemiaOctreotideRefractoryInternal medicineInternal MedicinemedicineHumansInsulinOral glucose toleranceSevere disorderGlucose tolerance testReactive hypoglycemiaC-Peptidemedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseHypoglycemiaSomatostatin AnaloguePostprandialEndocrinologyFoodbusinessArchives of Internal Medicine
researchProduct

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived…

2000

Abstract Dendritic cell (DC) vaccination, albeit still in an early stage, is a promising strategy to induce immunity to cancer. We explored whether DC can expand Ag-specific CD8+ T cells even in far-advanced stage IV melanoma patients. We found that three to five biweekly vaccinations of mature, monocyte-derived DC (three vaccinations of 6 × 106 s.c. followed by two i.v. ones of 6 and 12 × 106, respectively) pulsed with Mage-3A2.1 tumor and influenza matrix A2.1-positive control peptides as well as the recall Ag tetanus toxoid (in three of eight patients) generated in all eight patients Ag-specific effector CD8+ T cells that were detectable in blood directly ex vivo. This is the first time …

CD4-Positive T-LymphocytesCytotoxicity Immunologicmedicine.medical_treatmentInjections SubcutaneousImmunologyImmunization SecondaryEpitopes T-LymphocyteCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesMonocytesViral Matrix ProteinsAntigens NeoplasmTetanus ToxoidImmunology and AllergyMedicineCytotoxic T cellHumansMelanomaCells Culturedbusiness.industryMelanomaToxoidCell DifferentiationDendritic cellDendritic Cellsmedicine.diseaseNeoplasm ProteinsImmunizationImmunologyInjections IntravenousIntercellular Signaling Peptides and ProteinsbusinessPeptidesAdjuvantCD8Ex vivoT-Lymphocytes Cytotoxic
researchProduct

Clinical and Neurophysiological Follow-Up of Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with Subcutaneous Immunoglobulins: A …

2022

Background: chronic idiopathic demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated neuropathy characterized by weakness, sensory symptoms and significant reduction or loss of deep tendon reflexes evolving over 2 months at least, associated with electrophysiological evidence of peripheral nerve demyelination. Recently, subcutaneous immunoglobulins (SCIg) have been introduced in clinical practice as a maintenance therapy for CIDP; nevertheless, electrophysiological and efficacy data are limited. Methods: to evaluate SCIg treatment efficacy, we retrospectively reviewed data from 15 CIDP patients referring to our clinic, receiving SCIg treatment and who performed electrophysiolo…

CIDP; SCIg; cMAP; SNAP; ISS; INCAT; MRC; subcutaneous immunoglobulinMRCcMAPISSGeneral NeuroscienceSettore MED/26 - NeurologiaCIDPSNAPsubcutaneous immunoglobulinINCATSCIg
researchProduct

Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment

2014

Background We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI. Herein we compare these effects to once weekly, subcutaneous (s.c.) injection. The bioavailability of injected PPS is greater than oral, suggesting better delivery to difficult tissues such as bone and cartilage. Injected PPS also effectively treats osteoarthritis in animals, and has shown success in osteoarthritis patients. Methodology/principal findings One-month-old MPS VI rats were given once weekly s.c. injections of PPS (1, 2 and 4 mg/kg, human equivalent dose (HED)), or daily oral PPS (4 mg/kg HED) for 6 months. Serum inflammato…

Cartilage ArticularMaleMucopolysaccharidosisMucopolysaccharidosis type VIlcsh:MedicineAdministration OralOsteoarthritisOral administrationMedicine and Health SciencesFemurGrowth Platelcsh:Sciencehealth care economics and organizationsGlycosaminoglycansPentosan Sulfuric PolyesterMucopolysaccharidosis VIMultidisciplinaryMucopolysaccharidosis VIPentosan polysulfateBiomechanical Phenomena3. Good healthFemaleAnatomyResearch Articlemedicine.drugmedicine.medical_specialtyInflammatory DiseasesInjections SubcutaneousMovementeducationUrologyBiological AvailabilityResearch and Analysis MethodsDrug Administration ScheduleAutosomal Recessive DiseasesGeneticsmedicineAnimalsAnimal Models of DiseaseBoneAdverse effectMolecular BiologyClinical GeneticsDose-Response Relationship Drugbusiness.industrylcsh:RTherapeutic effectBiology and Life SciencesMucopolysaccharidosesmedicine.diseaseSpineRatsSurgeryAnimal Studieslcsh:QVeterinary ScienceTomography X-Ray ComputedbusinessPLoS ONE
researchProduct

3D and multispectral imaging for subcutaneous veins detection.

2009

The first and perhaps most important phase of a surgical procedure is the insertion of an intravenous (IV) catheter. Currently, this is performed manually by trained personnel. In some visions of future operating rooms, however, this process is to be replaced by an automated system. Experiments to determine the best NIR wavelengths to optimize vein contrast for physiological differences such as skin tone and/or the presence of hair on the arm or wrist surface are presented. For illumination our system is composed of a mercury arc lamp coupled to a 10nm band-pass spectrometer. A structured lighting system is also coupled to our multispectral system in order to provide 3D information of the p…

Diagnostic ImagingOptics and PhotonicsComputer sciencemedia_common.quotation_subjectMultispectral imageImage processingInfusions Subcutaneouslaw.inventionCatheterizationVeinsAutomationOpticsImaging Three-DimensionallawMedical imagingImage Processing Computer-AssistedContrast (vision)Humansmedia_commonModels StatisticalSpectroscopy Near-InfraredSpectrometerOrientation (computer vision)business.industryEquipment DesignMercuryLinear discriminant analysisImage EnhancementAtomic and Molecular Physics and OpticsSpectrophotometryArc lampbusinessOptics express
researchProduct

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1993

Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy nec…

DiarrheaMaleLoperamidemedicine.medical_specialtyAbdominal painCancer Researchmedicine.medical_treatmentInjections SubcutaneousOctreotideAdministration OralOctreotideGastroenterologyLoperamidelaw.inventionRandomized controlled triallawChemotherapy-related diarrheaInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)PharmacologyChemotherapybusiness.industryMiddle AgedClinical trialDiarrheaEndocrinologyOncologyChemotherapy-related diarrhea; Loperamide; Octreotide; Cancer Research; Oncology; PharmacologyDefecationFemalemedicine.symptombusinessmedicine.drug
researchProduct

Acute renal failure and liver dysfunction after subcutaneous injection of 3-sn-phosphatidylcholine (Lipostabil®)-case report.

2011

INTRODUCTION Drug-induced tubulointerstitial nephritis and acute tubular necrosis are common, and are often caused by drugs especially antibiotics or non-steroidal anti-inflammatory drugs. Drug-induced liver dysfunction and renal failure after subcutaneous injection of phosphatidylcholine was not reported so far. 3-sn-Phosphatidylcholine has been described as a cell lysis reaction-inducing drug. Its in vitro data indicated a relevant toxicity potential. In particular human cell types such as fibroblast-like preadipocytes, vascular and skeletal muscle cells, or renal epithelial cells react more sensitive than other human cell types. CASE REPORT We present a 28-year-old woman who received 3.5…

DrugAdultmedicine.medical_specialtymedicine.drug_classNauseamedia_common.quotation_subjectInjections SubcutaneousAntibioticsUrologyRenal functionSubcutaneous injectionmedicineHumansFat embolismAcute tubular necrosismedia_commonNephritisbusiness.industryGastroenterologyAcute Kidney Injurymedicine.diseaseSurgeryToxicityPhosphatidylcholinesFemalemedicine.symptombusinessZeitschrift fur Gastroenterologie
researchProduct

Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site.

2019

The subcutaneous administration route is widely used to administer different types of drugs given its high bioavailability and rapid onset of action. However, the sensation of pain at the injection site might reduce patient adherence. Apart from a direct effect of the drug itself, several factors can influence the sensation of pain: needle features, injection site, volume injected, injection speed, osmolality, viscosity and pH of formulation, as well as the kind of excipients employed, including buffers and preservatives. Short and thin needles, conveniently lubricated and with sharp tips, are generally used to minimize pain, although the anatomic injection site (abdomen versus thigh) also …

Drugmedia_common.quotation_subjectInjections SubcutaneousPainReviewPain sensationmedicine.disease_causeSubcutaneous injectionSensationInjection sitemedicineHumansPharmacology (medical)media_commonPharmacologyBuffer compositionbusiness.industryOsmolar ConcentrationGeneral MedicineBioavailabilityInjection Site ReactionSubcutaneous injectionmedicine.anatomical_structurePharmaceutical PreparationsThighNeedlesAnesthesiaAbdomenPatient ComplianceVolume injectedIrritationbusinessPreservativesAdvances in therapy
researchProduct

Uncommon localizations of hydatid cyst. Review of the literature

2016

Introduction Hydatid disease is an endemic anthropozoonosis with usual localization in liver and lungs. Rarely it localizes in uncommon sites as spleen, skeleton, kidney, brain, cardiac muscle, peritoneum, sub cutis. Complications of uncommon localizations are the same that for usual ones. Material and methods Review of the literature on rare and atypical localization of hydatid cysts in soft tissues. Key-words used on Pub-Med [(echinococ OR hydatid) AND (soft tissue OR subcutaneous OR cutaneous)] without time limit. There were found 282 articles; 242 were excluded because of muscular or bone localizations. 40 were coherent. Results Different variables are taken into account: age, sex, geog…

Echinococcosis HepaticPathologymedicine.medical_specialtyEndemic DiseasesSaudi ArabiaCutisIndiaHydatid cystReviewDiseaseIranGlobal HealthPeritoneal Diseases030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineAfrica NorthernEchinococcosismedicineHumansCystSubcutaneous hydatid cystUncommon localizationSplenic DiseasesBrain DiseasesHydatid cyst; Review; Subcutaneous hydatid cyst; Uncommon localizations; SurgeryGeographic areabusiness.industrySoft tissueMini-Reviewmedicine.diseaseEchinococcosisEuropeHydatid cystHomogeneousKidney DiseasesSurgerybusiness030217 neurology & neurosurgeryGiornale di Chirurgia - Journal of Surgery
researchProduct